Geron Corporation's stock dropped 50% before its Q4 2024 earnings report, with Rytelo's revenue close to projections but new ...

Shares of Geron (NASDAQ:GERN) plunged 30% early Wednesday after the company released its Q4 earnings report. Geron reported a ...

Geron (NASDAQ: GERN) stock is getting crushed in Wednesday's trading. The company's share price was down 31.7% as of 3:50 p.m ...

Geron Corp (GERN) reports a robust cash reserve and key FDA approval for Rytelo, but faces flat revenue trends and leadership changes in its commercial strategy.

Geron shares fell 30% to $1.66 after the company reported a fourth-quarter loss that was wider than expected.

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

Reports Q4 revenue $47.54M, consensus $45.29M. “2024 was a terrific year for Geron (GERN) and for RYTELO, our first-in-class telomerase ...

Thanks for joining us today. 2024 was a terrific year for Geron and for RYTELO, our first-in-class telomerase inhibitor. RYTELO has a unique mechanism of action that represents a highly ...

For Geron Corporation GERN, 2024 was a transformational year as it saw the FDA approval and commercial launch of Rytelo (imetelstat) for the treatment of low- to intermediate-1 risk ...

Geron ended 2024 with a strong cash position and reported that revenues for the third and fourth quarters exceeded expectations. The company's net product revenue for RYTELO reached $47.5 million in ...

Sales for the company's Rytelo treatment appear to be stagnating. Geron stock is seeing huge sell-offs on the heels of the company's recent fourth-quarter report and commentary. Despite sales for ...

Achieved $47.5 million in RYTELO™ (imetelstat) net product revenue in Q4 2024 and $76.5 million since commercial launch at the end of June 2024, following FDA approval Expect to reach ...